No connection

Search Results

Corporate Score 56 Neutral

Biogen Snaps Up Apellis Pharma For $5.6 Billion, But Biogen Dives As Apellis Soars

Mar 31, 2026 13:02 UTC
BIIB, APLS, XBI, IBB
Immediate term

Biogen Snaps Up Apellis Pharma For $5.6 Billion, But Biogen Dives As Apellis Soars.

  • Biogen is acquiring Apellis Pharma for $5.6 billion
  • Apellis shares are rising while Biogen shares are falling on the acquisition announcement

Biogen (BIIB) is bulking up its non-neurology profile with the $5.6 billion takeover of Apellis Pharmaceuticals (APLS). But Biogen stock slipped Tuesday following the announcement while Apellis shares soared. Adam Keeney, Biogen's executive vice president and head of corporate development, says it will probably take some time for analysts to wrap their heads around the story. Apellis sells Syfovre, a…

Sign up free to read the full analysis

Create a free account to unlock full AI-curated market articles, personalized alerts, and more.

Create Free Account Already have an account? Sign In
Share this article

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Get Started Free View Plans
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile